Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07224399 · ClinicalTrials.gov registry record · Phase 1
Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM1812 Injection Following Single and Multiple Subcutaneous Administration in Normal to Overweight or Obese But Otherwise Healthy Men and Women
A Phase 1 study of Overweight or Obesity and Healhty, sponsored by BrightGene Bio-Medical Technology Co..
- Recruiting
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT07224399: Recruiting Phase 1 study of Overweight or Obesity and Healhty, sponsored by BrightGene Bio-Medical Technology Co..
NCT07224399 is a Phase 1 study of Overweight or Obesity and Healhty that is actively recruiting participants, run by BrightGene Bio-Medical Technology Co.. The registered enrollment target is 60 participants, below the 31,711-participant average among 32 other Overweight or Obesity trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07224399, a Phase 1 study of Overweight or Obesity and Healhty, is actively recruiting participants, sponsored by BrightGene Bio-Medical Technology Co..
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a Phase 1, single-center, double-blind, placebo-controlled, dose-escalation study. The study will evaluate the pharmacokinetics (PK), pharmacodynamic (PD), preliminary efficacy, safety and tolerability of BGM1812 following single and multiple SC administrations in normal to overweight or obese but otherwise healthy subjects.
Primary Outcome
The relationship of each adverse event to the investigational product was assessed by the investigator
Conditions Studied
Interventions
- DRUG Placebo
- DRUG BGM1812
Study Locations (1)
Maryland
- Pharmaron CPC, Inc - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2025-10-09 |
| Est. Completion | 2026-05-15 |
| Phase | Phase 1 |
What NCT07224399 shows while recruiting
NCT07224399 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 31,711-participant average among 32 other Overweight or Obesity trials with a reported enrollment target (100% lower).
The record links to 2 conditions, with Overweight or Obesity appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07224399 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT07224399 about?
NCT07224399 is a clinical study titled "Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM1812 Injection Following Single and Multiple Subcutaneous Administration in Normal to Overweight or Obese But Otherwise Healthy Men and Women". This is a Phase 1, single-center, double-blind, placebo-controlled, dose-escalation study. The study will evaluate the pharmacokinetics (PK), pharmacodynamic (PD), preliminary efficacy, safety and tolerability of BGM1812 following single and multiple SC administrations in normal to overweight or obe...
What is the current status of trial NCT07224399?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2025-10-09. Estimated completion is 2026-05-15.
What conditions does trial NCT07224399 study?
This clinical trial studies the following conditions: Overweight or Obesity, Healhty.
What interventions are being tested in trial NCT07224399?
The interventions under investigation include: Placebo (DRUG), BGM1812 (DRUG).
Who is sponsoring clinical trial NCT07224399?
This trial is sponsored by BrightGene Bio-Medical Technology Co., which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07224399 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Overweight or Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07224399's enrollment target sits among peer trials
60 25th of 32 higher than 8 of 32 other Overweight or Obesity trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Overweight or Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of LY4064912 in Healthy Participants and With Overweight or Obesity
RECRUITING · Phase 1
-
Remotely Delivered Resistance Training for Cardiometabolic Health Among Black Women
RECRUITING · NA
-
NDPP-NextGen: A Clinical Trial to Reduce Intergenerational Obesity and Diabetes Risks
RECRUITING · NA
-
Better Lifestyle Counseling for African American Women During Pregnancy
RECRUITING · NA
-
Community Park-Based Programs for Health Promotion: The Fit2Lead Prospective Cohort Study
RECRUITING
-
eMOTION: Examining Implicit Attitudes in Physical Activity Engagement
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI